GlassScriptPhysician profile
Varuni Rao
NPI 1396032215
$5,808.64
in general payments reported to CMS, 2019-2025
43 companies · $937 in 2025
The $937 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.59 · 2020: $547 · 2021: $1,469 · 2022: $1,015 · 2023: $993 · 2024: $791 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689 · Education: $31.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.19 |
| Education | $31.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.29 | 2019-2025 | |
| Amgen INC. | $850.99 | 2020-2025 | Krystexxa, Uplizna, Enbrel |
| Ucb, INC. | $610.23 | 2020-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $489.73 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $228.21 | 2019-2025 | Saphnelo |
| Pfizer INC. | $221.01 | 2021-2024 | |
| Horizon Therapeutics Plc | $190.15 | 2020-2023 | Krystexxa |
| Sk Life Science, INC. | $166.58 | 2020-2023 | |
| Janssen Biotech, INC. | $161.08 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $159.20 | 2019-2025 | |
| Inspire Medical Systems, INC. | $94.19 | 2024-2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $79.09 | 2021 | |
| Scilex Pharmaceuticals INC. | $77.43 | 2024-2025 | |
| Genentech USA, INC. | $67.35 | 2021-2025 | Gazyva |
| Jazz Pharmaceuticals INC. | $62.53 | 2020-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varuni Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.